All, ...News..... Xillix forms partnership with Cadmit Inc.
Xillix Technologies Corp XLX
Shares issued 31,786,474 Jun 4 close $1.23
Mon 7 Jun 99 News Release
Mr. Pierrre Leduc reports
Xillix Technologies and Cadmit Inc. of Toronto, Ont., have formed a
partnership to develop innovative technologies for improving cancer
treatment planning and dosimetry (dosimetry is the science of measuring the
therapeutic dose delivered to a patient and the effectiveness of a cancer
treatment) integrating the Xillix Life fluorescence imaging system. Cadmit
will conduct research through its affiliate, the Ontario Cancer Institute,
the Research Institute of the Princess Margaret Hospital in Toronto.
Cadmit will provide research for Xillix in three areas: in-vivo optical
imaging; photodynamic fluorescence imaging and photodynamic dosimetry.
Xillix gains the right of first refusal for technology or products
resulting from research conducted in these areas.
"Cadmit's experience in conducting research and their direct access to a
world class scientific and clinical testing environment at the Ontario
Cancer Institute will enable us to integrate our proprietary fluorescence
imaging technology to an improved cancer management methodology," said
Pierrre Leduc, president and chief executive officer of Xillix. "We have
worked with this scientific team for the past five years in developing our
next generation product and we are pleased to formalize this agreement."
"Through our partnership with Xillix we will be in a position to enter the
photodynamic therapy treatment planning and dosimetry market," said Michael
Sherar, president of Cadmit, senior scientist at the Ontario Cancer
Institute and Associate Professor in the Department of Medical Biophysics
at the University of Toronto. "Photodynamic therapy planning and dosimetry
is an emerging market and our goal, along with Xillix, is to become the
world market leaders."
The company's lead product, called the Xillix Life-Lung Fluorescence
Endoscopy System, has been approved for sale in the United States, Canada,
Europe and Japan. Worldwide marketing has been granted to Olympus Optical
Co. Ltd., of Tokyo, the international endoscopy market leader.
Cadmit was formed in 1998 and is focused on developing computer software
and enabling medical hardware for planning and dosimetry of minimally
invasive therapies including photodynamic therapy and thermal therapy.
Ontario Cancer Institute is the Research Institute of the Princess Margaret
Hospital in Toronto. Princess Margaret Hospital, a teaching hospital of the
University of Toronto and member of the University Health Network, has
achieved an international reputation as a global leader in the fight
against cancer and is considered one of the top comprehensive cancer
treatment and research centres in the world.
(c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com |
